NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis $0.59 -0.01 (-1.67%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Amarin alerts: Email Address About Amarin Stock (NASDAQ:AMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amarin alerts:Sign Up Key Stats Today's Range$0.59▼$0.6050-Day Range$0.58▼$0.8052-Week Range$0.57▼$1.37Volume561,644 shsAverage Volume1.66 million shsMarket Capitalization$242.34 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingHold Company OverviewAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Read More… Forget Trump and Kamala (Ad)I hope you're deleting all those emails telling you how to make "1,000% gains" from the magic "Kamala Trade". It's nonsense. No one knows what's going to happen in November.THIS CALENDAR is the only thing that matters for you and your financial health right now. Amarin Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 33rd PercentileAmarin scored higher than 33% of companies evaluated by MarketBeat, and ranked 799th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAmarin has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAmarin has received no research coverage in the past 90 days.Read more about Amarin's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.18) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amarin's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.38% of the outstanding shares of Amarin have been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Amarin has recently decreased by 3.39%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.38% of the outstanding shares of Amarin have been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Amarin has recently decreased by 3.39%, indicating that investor sentiment is improving. News and Social Media0.7 / 5News Sentiment-0.66 News SentimentAmarin has a news sentiment score of -0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Amarin this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.96% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 22.25% of the stock of Amarin is held by institutions.Read more about Amarin's insider trading history. Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRN Stock News HeadlinesHere's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn SituationSeptember 18 at 10:26 AM | finance.yahoo.comAura Biosciences: Highly Derisked Late-Stage Eye Cancer CompanySeptember 17 at 2:24 PM | seekingalpha.comAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt industries worth over $46 trillion. What's even more intriguing?September 20, 2024 | InvestorPlace (Ad)Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) MeetingSeptember 9, 2024 | globenewswire.comAmarin Corp PLC (EH3A.DU)September 4, 2024 | sg.finance.yahoo.comLatest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) CongressAugust 22, 2024 | globenewswire.comAmarin Corp (NASDAQ:AMRN) Stock Quotes, Forecast and News SummaryAugust 17, 2024 | benzinga.comAmarin’s Stock Maintains Hold Rating Amidst Revenue Highs and Market ChallengesAugust 5, 2024 | markets.businessinsider.comSee More Headlines AMRN Stock Analysis - Frequently Asked Questions How have AMRN shares performed this year? Amarin's stock was trading at $0.87 at the beginning of the year. Since then, AMRN stock has decreased by 32.2% and is now trading at $0.5901. View the best growth stocks for 2024 here. How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) announced its quarterly earnings data on Wednesday, May, 1st. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company had revenue of $56.52 million for the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative trailing twelve-month return on equity of 6.09% and a negative net margin of 12.66%. Does Amarin have any subsidiaries? Amarin subsidiaries include these companies: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited. Who are Amarin's major shareholders? Top institutional shareholders of Amarin include Longitude Cayman Ltd. (0.58%), Waterfront Wealth Inc. (0.21%), Cutter & CO Brokerage Inc. (0.10%) and Prospect Financial Services LLC (0.01%). Insiders that own company stock include Aaron Berg, Steven B Ketchum, Patrick Holt, Olsen Per Wold and Joseph S Zakrzewski. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA) and Tesla (TSLA). Company Calendar Last Earnings5/01/2024Today9/20/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMRN CUSIPN/A CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees360Year Founded1991Price Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Potential Upside/Downside+69.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,110,000.00 Net Margins-12.66% Pretax Margin-10.20% Return on Equity-6.09% Return on Assets-4.11% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio2.01 Sales & Book Value Annual Sales$264.78 million Price / Sales0.92 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book0.44Miscellaneous Outstanding Shares410,672,000Free Float402,623,000Market Cap$242.34 million OptionableOptionable Beta1.92 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:AMRN) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.